ClinicalTrials.gg
CompletedNCT02123667ATLANTISUpdated Sep 10, 2026

AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)

An observational study in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 26 sites in 8 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Chiesi Farmaceutici S.p.A. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
872
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
4th of 15
872 · median 300
Started
2014
with 4 others
Observational
15 of 81
6 open now
Registered
39th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 4th largest by enrollment of the 15 observational ones that give a count, is one of 5 that started in 2014, is one of 15 observational ones, and was the 39th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Multinational, multicentre, non-pharmacological intervention, cross-sectional and longitudinal study.

Read the detailed description

Large non pharmacological studies on Small Airways Disease

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

900 subjects divided into 800 asthmatic patients and 100 healthy controls will be included. Recruitment will be balanced, at the extent possible, in order to achieve at least > 150 patients each for steps 1 - 4 and > 50 patients for step 5 as indicated in the international guidelines (GINA 2012) on the basis of their previous therapy. The 150 healthy controls will be recruited on the basis of absence of respiratory symptoms, airway obstruction and hyper responsiveness.

Eligibility criteria

Asthmatic patient inclusion criteria

  1. Male or female patients aged ≥ 18 and ≤ 65 years, who have signed an form
  2. Clinical diagnosis of asthma f

    1. Positive response to methacholine challenge test
    2. Positive response to a reversibility test or
    3. Peak Flow variability (i.e. highest - lowest PEF over the day/mean value of the two, × 100) > 20% or
    4. Documented response (defined as Δ ≥ 12% and ≥ 200 mL) after a cycle (e.g., 4 weeks) of regular maintenance anti-asthma treatment.
  3. Patients with stable asthma.
  4. Current smoker, ex-smoker or lifelong non-smoker Healthy subject inclusion criteria

1. Male or female patients aged ≥ 18 and ≤ 65 years 2. No clinical history of asthma or 3. Current smoker, ex-smoker or lifelong non-smokers 4. Normal spirometry 5. Normal airways responsiveness Asthmatic patient exclusion criteria

  1. Cigarette smoking > 10 packyears
  2. diagnosis of COPD
  3. Asthma exacerbation in the 8 weeks prior to baseline visit
  4. Clinical or functional uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that might compromise the results or interpretation of the study.
  5. Pregnant or lactating women
  6. Participation in an interventional clinical trial \<12 weeks preceding baseline visit
  7. Inability to comply with study procedures.
  8. Alcohol or drug abuse. Healthy subject exclusion criteria

1. Cigarette smoking history > 10 packyears 2. Diagnosed upper and/or lower respiratory disease(s). 3. Clinical or functional uncontrolled haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that mightp compromise the results or interpretation of the study.

4. Pregnant or lactating women 5. Participation in an interventional clinical trial \<12 weeks preceding baseline visit 6. Inability to comply with study procedures. 7. Alcohol or drug abuse.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
872 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Asthmatic patients

    asthmatic patients 18 to 65

  • Healthy volunteers

    Volunteers 18 to 65

06

What researchers measure

Primary outcomes

  1. To determine the role of small airways abnormalities in the clinical manifestations of asthma.

    Time frame: 1 year

07

Study locations

26 sites
  • Chiesi Clinical Trial Site #0503
    Denver, Colorado 80206, United States
  • Chiesi Clinical Trial Site #0502
    Durham, North Carolina 27710, United States
  • Chiesi Clinical Trial Site #0504
    Cleveland, Ohio 44106, United States
  • Chiesi Clinical Trial Site #0501
    Houston, Texas 77030, United States
  • Prof. Dr. Emilio Pizzichini
    Florianópolis, Brazil
  • Prof. Dr. Alberto Cukier
    São Paulo, Brazil
  • Prof. Dr. Rafael Stelmach
    São Paulo, Brazil
  • Chiesi Clinical Trial Site #0201
    Montreal, Quebec H2X 2P4, Canada
  • Gao
    Beijing, Beijing Municipality 100730, China
  • Yuanlin Song
    Shanghai, Shanghai Municipality 200032,, China
  • Qingling Zhang
    Hangzhou, 510120, China
  • Chiesi Clinical Trial Site #0303
    Großhansdorf, D-22927, Germany
  • Chiesi Clinical Trial Site #0301
    Hanover, 30625, Germany
  • Chiesi Clinical Trial Site #0302
    Leipzig, D-04357, Germany
  • Chiesi Clinical Trial Site #0104
    Ferrara, 44124, Italy
  • Chiesi Clinical Trial Site #0101
    Naples, Italy
  • Scichilone
    Palermo, Italy
  • Chetta
    Parma, Italy
  • Chiesi Clinical Trial Site #0103
    Pisa, 56124, Italy
  • Chiesi Clinical Trial Site #0102
    Verona, 37134, Italy
  • Dr. M. Broeders
    's-Hertogenbosch, Netherlands
  • W. Boersma
    Alkmaar, Netherlands
  • Dr. J. Vroegop
    Groningen, Netherlands
  • Dr. M. vd Berge
    Groningen, Netherlands
  • Chiesi Clinical Trial Site #0402
    Barcelona, 08026, Spain
  • Chiesi Clinical Trial Site #0401
    Lugo, 27003, Spain
08

References and documents

Publications

  • Kole TM, Vanden Berghe E, Kraft M, Vonk JM, Nawijn MC, Siddiqui S, Sun K, Fabbri LM, Rabe KF, Chung KF, Nicolini G, Papi A, Brightling C, Singh D, van der Molen T, Dahlen SE, Agusti A, Faner R, Wedzicha JA, Donaldson GC, Adcock IM, Lahousse L, Kerstjens HAM, van den Berge M; ATLANTIS; U-BIOPRED; CADSET investigators. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study. Lancet Respir Med. 2023 Jan;11(1):55-64. doi: 10.1016/S2213-2600(22)00185-0. Epub 2022 Jul 27. PubMed 35907424 ↗
  • Galant SP, Kuks PJM, Kole TM, Kraft M, Siddiqui S, Fabbri LM, Beghe B, Rabe KF, Papi A, Brightling CE, Singh D, Kocks JWH, Franzini L, Vonk JM, Kerstjens HAM, Heijink IH, Pouwels SD, Slebos DJ, van den Berge M. Assessment of the role of small airway dysfunction in relation to exacerbation risk in patients with well controlled asthma (ATLANTIS): an observational study. Lancet Respir Med. 2025 Nov;13(11):990-1000. doi: 10.1016/S2213-2600(25)00283-8. Epub 2025 Sep 29. PubMed 41038213 ↗
  • Karp T, Merid SK, Kermani NZ, Faiz A, Gillett TE, Bults R, Raby KL, Kerstjens HAM, Nawijn MC, Piraino A, Kraft M, Beghe B, Rabe KF, Papi A, Brightling C, Singh D, Kocks JH, Siddiqui S, Adcock IM, Chung KF, Bhavsar P, Koppelman GH, Melen E, Guryev V, van den Berge M. Nasal gene expression shows a distinct signature in type 2-high asthma but not in type 2-low disease. J Allergy Clin Immunol. 2026 Apr;157(4):879-889. doi: 10.1016/j.jaci.2025.10.036. Epub 2026 Jan 2. PubMed 41485495 ↗
  • Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med. 2019 May;7(5):402-416. doi: 10.1016/S2213-2600(19)30049-9. Epub 2019 Mar 12. PubMed 30876830 ↗
  • Kole TM, Muiser S, Kraft M, Siddiqui S, Fabbri LM, Rabe KF, Papi A, Brightling C, Singh D, van der Molen T, Nawijn MC, Kerstjens HAM, van den Berge M. Sex differences in asthma control, lung function and exacerbations: the ATLANTIS study. BMJ Open Respir Res. 2024 Jun 19;11(1):e002316. doi: 10.1136/bmjresp-2024-002316. PubMed 38901877 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Mar 2017, 32 months.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's 32 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2014
First posted
Apr 25, 2014
StartActual
Jun 30, 2014
Primary completionActual
Mar 4, 2017
CompletionActual
Mar 4, 2017
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02123667
Responsible party
Sponsor
First posted
Apr 25, 2014
Start date
Jun 30, 2014
Primary completion
Mar 4, 2017
Completion
Mar 4, 2017
Last update
Sep 10, 2026

Study contacts

Monica Kraft, MD
principal investigator · Duke University
Dirkje S Postma, Prof. Dr.
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion